Compare LAW & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAW | ADCT |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 466.2M | 484.4M |
| IPO Year | 2021 | 2019 |
| Metric | LAW | ADCT |
|---|---|---|
| Price | $3.42 | $4.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $8.00 | $7.50 |
| AVG Volume (30 Days) | 608.6K | ★ 717.8K |
| Earning Date | 05-25-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 22.58 | ★ 44.90 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $156,849,000.00 | $70,837,000.00 |
| Revenue This Year | $9.74 | $13.66 |
| Revenue Next Year | $9.78 | $2.15 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.29 | 1.84 |
| 52 Week Low | $2.45 | $1.05 |
| 52 Week High | $9.11 | $4.80 |
| Indicator | LAW | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 38.28 | 54.89 |
| Support Level | N/A | $3.25 |
| Resistance Level | $4.48 | $4.32 |
| Average True Range (ATR) | 0.41 | 0.25 |
| MACD | 0.09 | -0.00 |
| Stochastic Oscillator | 65.64 | 48.29 |
CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).